1-8 of 8
Craig Thomas Wallington-Beddoe
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

Sundar Jagannath, Thierry Facon, Ashraf Z. Badros, Moshe Levy, Philippe Moreau, Sosana Delimpasi, Maryana Simonova, Ivan Spicka, Iryna Kriachok, Maria Gavriatopoulou, Halyna Pylypenko, Holger W Auner, Xavier Leleu, Vadim Doronin, Ganna Usenko, Roman Hajek, Reuben Benjamin, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Chris P. Venner, Mamta Garg, Mercedes Gironella Mesa, Artur Jurczyszyn, Tadeusz Robak, Monica Galli, Craig Thomas Wallington-Beddoe, Atanas Radinoff, Galina Salogub, Don Stevens, Supratik Basu, Anna Marina Liberati, Hang Quach, Veselina S Goranova Marinova, Jelena Sreten Bila, Eirini Katodritou, Andrew DeCastro, Yi Chai, Dane R. Van Domelen, Moran Mishal, Ohad S. Bentur, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Sebastian Grosicki, Paul G. Richardson
Journal: Blood
Blood (2021) 138 (Supplement 1): 3793.
https://doi.org/10.1182/blood-2021-146003
Published: 2021
Journal Articles

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Peter Mollee, John Reynolds, Wojciech Janowski, Hang Quach, Philip Campbell, Simon D. Gibbs, Sophie Lee, James D'Rozario, Kerry Taylor, Tara Cochrane, Craig Thomas Wallington-Beddoe, Fiona Kwok, Nicholas Weber, Ian H Kerridge, Helen Weston, P. Joy Ho, Noemi Horvath, Flora Yuen, Andrew Spencer
Journal: Blood
Blood (2021) 138 (Supplement 1): 2728.
https://doi.org/10.1182/blood-2021-152500
Published: 2021
Journal Articles

The Effect of Daratumumab, Lenalidomide, Dexamethasone (DRd) on Peripheral Blood Stem Cell Mobilisation (PBSC)

Tishya Indran, Michael Swain, Jacqueline Widjaja, Flora Yuen, Hang Quach, Wojt Janowski, Anna Hutchinson, Craig Thomas Wallington-Beddoe, Jane Estell, Ian H Kerridge, Andrew Spencer
Journal: Blood
Blood (2021) 138 (Supplement 1): 3884.
https://doi.org/10.1182/blood-2021-150444
Published: 2021
Journal Articles

Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Sueh-li Lim, John Reynolds, Hang Quach, Anna Hutchinson, Ian H Kerridge, Jane Estell, Wojt Janowski, Craig Thomas Wallington-Beddoe, Anna Kalff, Flora Yuen, Andrew Spencer
Journal: Blood
Blood (2021) 138 (Supplement 1): 1665.
https://doi.org/10.1182/blood-2021-152102
Published: 2021
Journal Articles

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Slavisa Ninkovic, Nicholas E. Murphy, Hasib Sidiqi, Craig Thomas Wallington-Beddoe, Anish Puliyayil, Costas K. Yannakou, Wojt Janowski, Flora Yuen, Andrew Spencer, Hang Quach
Journal: Blood
Blood (2021) 138 (Supplement 1): 1671.
https://doi.org/10.1182/blood-2021-151871
Published: 2021
Journal Articles

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Peter Mollee, FRACP,MBBS,MSc,FRCPA, John Reynolds, PhD, Wojt Janowski, FRCPA,FRACP, Hang Quach, MDFRACP,FRCPA,MBBS, Philip Campbell, MBBS, Simon D. Gibbs, FRACP, FRCPA, MBBS, Sophie Lee, FRACP, FRCPA, PhD, James D'Rozario, MBBS, FRACP, FRCPA, Kerry Taylor, FRACP,FRCPA,MBBS, Tara Cochrane, MBBS,FRCPA,FRACP, Craig Thomas Wallington-Beddoe, BSc,MBBS,PhDFRACP,FRCPA, Fiona Kwok, FRACP,FRCPA,MBBS, Nicholas Weber, MBBS, Ian H. Kerridge, FRACP FRCPA MPhil BA, Helen Weston, MBBS, FRACP, FRCPA, Phoebe Joy Ho, MBBS,DPhil,FRACP,FRCPA, Noemi Horvath, MB ChB FRACP FRCPA, Flora Yuen, BBiomedSc, Andrew Spencer
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–5.
https://doi.org/10.1182/blood-2020-138394
Published: 2020
Journal Articles

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Anna Kalff, MBBS, Jake Shortt, MBBS FRACP FRCPA PhD, Flora Yuen, BBiomedSc, John Reynolds, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, Craig Thomas Wallington-Beddoe, BSc,MBBS,PhDFRACP,FRCPA, Patricia Walker, MBBS, BMedSci, FRACP, FRCPA, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Rosanne Dunn, PhD, Andrew Spencer, DM
Journal: Blood
Blood (2019) 134 (Supplement_1): 3144.
https://doi.org/10.1182/blood-2019-130084
Published: 2019
Journal Articles

Phase 2 Trial of the Combination of Ixazomib, Thalidomide and Dexamethasone (ITD) in Relapsed/Refractory Myeloma: Planned Preliminary Analysis

Krystal Bergin, Flora Yuen, BBiomedSc, Craig Thomas Wallington-Beddoe, BSc, MBBS, PhD FRACP, FRCPA, Anna Kalff, MBBS, Shreerang Sirdesai, MBBS, FRACP, FRCPA, John Reynolds, PhD, Andrew Spencer, MBBS, MD FRACP, FRCPA
Journal: Blood
Blood (2018) 132 (Supplement 1): 3265.
https://doi.org/10.1182/blood-2018-99-118172
Published: 2018